Major biotech firms MBX Biosciences and uniQure attracted substantial nine-figure fundraising rounds, reflecting sustained investor confidence in life sciences despite political and economic uncertainties. Venture funding reports detail multiple $50 million-plus rounds including Avenzo, AusperBio, Ensoma, and Sparrow. These capital infusions underpin advancements in gene therapies, precision oncology, and biologics manufacturing. Concurrently, Eli Lilly inaugurated a new incubator site in San Diego, supporting early-stage biotechs and fostering innovation hubs.